Increased risk of a herpes zoster attack in patients receiving androgen deprivation therapy for prostate cancer

F. J. Wu, L. T. Kao, S. Y. Sheu, H. C. Lin, S. D. Chung

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This study aimed to examine the association of herpes zoster (HZ) with androgen deprivation therapy (ADT) use among patients with prostate cancer (PC), using a population-based data set. The study sample for this study was retrieved from the Taiwan Longitudinal Health Insurance Database 2005. We selected 877 patients with PC who had received ADT as the study group, while 849 patients with PC who had not received ADT served as the comparison group. Each study patient was individually tracked for a 3-year period to discriminate those who subsequently received a diagnosis of HZ. Of the total 1,726 sampled patients, the incidence rate of HZ per 100 person-years was 1.80 (95% CI: 1.41–2.25) during the 3-year follow-up period. In particular, incidence rates of HZ per 100 person-years were 2.36 (95% CI: 1.75–3.13) and 1.24 (95% CI: 0.81–1.81), respectively, for patients with PC who had and those who had not received ADT. Furthermore, Cox proportional hazard regressions showed that the adjusted hazard ratio for an HZ attack during the 3-year follow-up period for patients with PC who had received ADT was 1.88 (95% CI: 1.13–3.11) than those who had not received ADT. We concluded that patients with PC who had received ADT had an increased risk of HZ.

Original languageEnglish
Article numbere12863
JournalAndrologia
Volume50
Issue number2
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Herpes Zoster
Androgens
Prostatic Neoplasms
Therapeutics
Incidence
Health Insurance
Taiwan
Databases
Population

Keywords

  • androgen deprivation therapy
  • herpes zoster
  • prostate cancer

ASJC Scopus subject areas

  • Endocrinology
  • Urology

Cite this

Increased risk of a herpes zoster attack in patients receiving androgen deprivation therapy for prostate cancer. / Wu, F. J.; Kao, L. T.; Sheu, S. Y.; Lin, H. C.; Chung, S. D.

In: Andrologia, Vol. 50, No. 2, e12863, 01.03.2018.

Research output: Contribution to journalArticle

@article{0e9ade751ae14403b7d078f5df1507c4,
title = "Increased risk of a herpes zoster attack in patients receiving androgen deprivation therapy for prostate cancer",
abstract = "This study aimed to examine the association of herpes zoster (HZ) with androgen deprivation therapy (ADT) use among patients with prostate cancer (PC), using a population-based data set. The study sample for this study was retrieved from the Taiwan Longitudinal Health Insurance Database 2005. We selected 877 patients with PC who had received ADT as the study group, while 849 patients with PC who had not received ADT served as the comparison group. Each study patient was individually tracked for a 3-year period to discriminate those who subsequently received a diagnosis of HZ. Of the total 1,726 sampled patients, the incidence rate of HZ per 100 person-years was 1.80 (95{\%} CI: 1.41–2.25) during the 3-year follow-up period. In particular, incidence rates of HZ per 100 person-years were 2.36 (95{\%} CI: 1.75–3.13) and 1.24 (95{\%} CI: 0.81–1.81), respectively, for patients with PC who had and those who had not received ADT. Furthermore, Cox proportional hazard regressions showed that the adjusted hazard ratio for an HZ attack during the 3-year follow-up period for patients with PC who had received ADT was 1.88 (95{\%} CI: 1.13–3.11) than those who had not received ADT. We concluded that patients with PC who had received ADT had an increased risk of HZ.",
keywords = "androgen deprivation therapy, herpes zoster, prostate cancer",
author = "Wu, {F. J.} and Kao, {L. T.} and Sheu, {S. Y.} and Lin, {H. C.} and Chung, {S. D.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1111/and.12863",
language = "English",
volume = "50",
journal = "Andrologia",
issn = "0303-4569",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Increased risk of a herpes zoster attack in patients receiving androgen deprivation therapy for prostate cancer

AU - Wu, F. J.

AU - Kao, L. T.

AU - Sheu, S. Y.

AU - Lin, H. C.

AU - Chung, S. D.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - This study aimed to examine the association of herpes zoster (HZ) with androgen deprivation therapy (ADT) use among patients with prostate cancer (PC), using a population-based data set. The study sample for this study was retrieved from the Taiwan Longitudinal Health Insurance Database 2005. We selected 877 patients with PC who had received ADT as the study group, while 849 patients with PC who had not received ADT served as the comparison group. Each study patient was individually tracked for a 3-year period to discriminate those who subsequently received a diagnosis of HZ. Of the total 1,726 sampled patients, the incidence rate of HZ per 100 person-years was 1.80 (95% CI: 1.41–2.25) during the 3-year follow-up period. In particular, incidence rates of HZ per 100 person-years were 2.36 (95% CI: 1.75–3.13) and 1.24 (95% CI: 0.81–1.81), respectively, for patients with PC who had and those who had not received ADT. Furthermore, Cox proportional hazard regressions showed that the adjusted hazard ratio for an HZ attack during the 3-year follow-up period for patients with PC who had received ADT was 1.88 (95% CI: 1.13–3.11) than those who had not received ADT. We concluded that patients with PC who had received ADT had an increased risk of HZ.

AB - This study aimed to examine the association of herpes zoster (HZ) with androgen deprivation therapy (ADT) use among patients with prostate cancer (PC), using a population-based data set. The study sample for this study was retrieved from the Taiwan Longitudinal Health Insurance Database 2005. We selected 877 patients with PC who had received ADT as the study group, while 849 patients with PC who had not received ADT served as the comparison group. Each study patient was individually tracked for a 3-year period to discriminate those who subsequently received a diagnosis of HZ. Of the total 1,726 sampled patients, the incidence rate of HZ per 100 person-years was 1.80 (95% CI: 1.41–2.25) during the 3-year follow-up period. In particular, incidence rates of HZ per 100 person-years were 2.36 (95% CI: 1.75–3.13) and 1.24 (95% CI: 0.81–1.81), respectively, for patients with PC who had and those who had not received ADT. Furthermore, Cox proportional hazard regressions showed that the adjusted hazard ratio for an HZ attack during the 3-year follow-up period for patients with PC who had received ADT was 1.88 (95% CI: 1.13–3.11) than those who had not received ADT. We concluded that patients with PC who had received ADT had an increased risk of HZ.

KW - androgen deprivation therapy

KW - herpes zoster

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85042130942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042130942&partnerID=8YFLogxK

U2 - 10.1111/and.12863

DO - 10.1111/and.12863

M3 - Article

AN - SCOPUS:85042130942

VL - 50

JO - Andrologia

JF - Andrologia

SN - 0303-4569

IS - 2

M1 - e12863

ER -